A Seattle biotechnology company, Immune Design, working on immune-based therapies to fight cancer, filed documents with the Securities and Exchange Commission to go public.
The biotech, on Eastlake Avenue East, said it wants to raise $60 million to finish the phase 1 clinical trials and to support continued development, including into phase 2 clinical trials.
The company's primary research and focus is on targeting tumors and killing them off through the body's immune system. The treatment is done through a series of injections on patients with melanoma, non-small cell lung cancer, breast cancer, ovarian cancer, sarcoma or Merkel cell carcinoma.
Immune Design has three clinic trials ongoing. The most recent, which began in
Most Popular Stories
- Prosecutor to Investigate Walmart Police Shooting
- GM to Announce New Jobs in Tennessee
- Michael Brown Funeral: Can Americans Change the Script of Violence?
- Emirates Hit Libyan Targets With Airstrikes
- Smith & Wesson Misses Target
- American Killed With ISIS Fighters in Syria
- Marco Rubio Warns Obama on Deportations
- Ford Hires 300 at Louisville Lincoln Plant
- Surf's Up! SoCal Prepares for Big Storm Surf
- Hamas Claims Gaza Ceasefire as Victory Over Israel